Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Santarus gets NA rights to Pharming's Rhucin; Pharming reacquires those rights

Executive Summary

Santarus Inc. (GI and metabolic therapeutics) has received exclusive North American marketing rights to Pharming Group NV's (treatments for genetic disorders and surgical and nutritional products) Rhucin (conestat; recombinant human C1 inhibitor) for acute attacks of hereditary angioedema (HAE) and other indications.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies